We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biopharma company Halozyme Therapeutics is on a mission to replace IV-drug delivery. It develops subcutaneous devices to make it easier and quicker to inject high-volume drugs into patients. Halozyme ...

Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $54.51 which represents a slight increase of $0.68 or 1.26% from the prior close of $53.83. The stock opened at $54.39 ...

Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) on January 12 and set a price target of ...

TD Cowen analyst Brendan Smith reiterated a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $77.00.Stay Ahead ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.55, a high estimate of $73.00, and a low estimate of $52.00. Marking an increase of 0.44%, the current ...

Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price objective raised by Piper Sandler from $52.00 to $53.00 in a report published on Friday,Benzinga reports. They currently have a neutral ...

Zacks Research increased their Q1 2025 EPS estimates for shares of Halozyme Therapeutics in a report released on Tuesday, ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Halozyme Therapeutics (HALO) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Research shows that ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...